Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-23T22:26:33.190Z Has data issue: false hasContentIssue false
  • English
  • Français

“Nothing More to Be Done”: Palliative Care Versus Exerimental Therapy in Advanced Cancer

Published online by Cambridge University Press:  26 September 2008

Ilana Löwy
Ilana Löwy
Affiliation:
U-158 INSERMHôpital Necker–Enfants Malades, Paris
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients suffering from advanced, incurable cancer often receive from their doctors proposals to enroll in a clinical trial of an experimental therapy. Experimental therapies are increasingly perceived not as a highly problematic approach but as a near-standard way to deal with incurable cancer. There are, however, important differences in the diffusion of these therapies in Western countries. The large diffusion of experimental therapies for malignant disease in the United States contrasts with the much more restricted diffusion of these therapies in the United Kingdom. The difference between the two reflects differences in the organization of health care in these countries and distinct patterns of the professionalization of medical oncology in America and in Britain. The high density and great autonomy of medical oncologists in the United States encourages there the diffusion of experimental therapies (regarded by some as expensive and inefficient); the lower density of these specialists in the United Kingdom and their task as consultants and not primary caregivers, favors the choice of more conservative (for some, too conservative) treatments. Theoretically, the decision as to whether patients suffering from advanced, incurable cancer will be steered toward an experimental therapy or toward palliative care depends on the values and beliefs of these patients and their physicians. In practice, however, such choice does not depend exclusively on the individual' cultural background and ethical values, but is also strongly affected by the — culturally conditioned — Professional and institutional structure of medicine

Type
Article
Information
Science in Context , Volume 8 , Issue 1 , Spring 1995 , pp. 209 - 229
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aaron, H. J. and Schwartz, W. B.. 1984. The Painful Prescription: Rationing Hospital Care. Washington, DC: The Brookings Institution.Google Scholar
Austoker, J. 1988. A History of the Imperial Cancer Research Fund 1902 –1986. Oxford: Oxford University Press.Google Scholar
Bernard, J. 1978. L‘Espe´rance ou le nouvel état de la mdicine. Paris: Buchet/Chastel.Google Scholar
Bisel, H. F. 1956.“Clinical Aspects of Cancer Chemotherapy Program.” Current Research in Cancer Chemotherapy 5: 6–14.Google Scholar
Braverman, A. S. 1991. “Medical Oncology in the 1990s. The Lancet i: 901–2.CrossRefGoogle ScholarPubMed
Brossat, S. and Pinell, P. 1990. “Coping with Parents.” Sociology of Health and Illness 12: 69–83.Google Scholar
Bud, R. F. 1978. “Strategy in American Cancer Research after World War II: A Case Study.” Social Studies of Science 8: 425–59.CrossRefGoogle Scholar
Burchenal, J. H. 1964. “Long-Term Remission in Acute Leukemia.” In Chemotherapy of Cancer, Plattner, P. A., 257–62. Amsterdam: Elsevier.Google Scholar
Buzdar, A. A. 1988. “What Is the Best for the Patient: A United States View.” In Cost versus Benefit in Cancer Care, Stoll, A. B.. Baltimore: The Johns Hopkins University Press.Google Scholar
Cassileth, B. R. 1979. “The Evolution of Oncology as a Sociomedical phenomenon.” In The Cancer Patient: Social and Medical Aspects of Care, Cassileth, B. R.. Philadelphia: Lea & Febiger.Google Scholar
Daniels, N. 1986. “Why Saying No to the Patients in the United States is So Hard:Cost Containment, Justice and Provider Authority.“ New England Journal of Medicine 314:80–83.CrossRefGoogle Scholar
DelVecchioGood, M. J. 1991. “The Practice of Biomedicine and the Discourse of Hope: A Preliminary Investigation into the Culture of American Oncology.“ Anthropologies of Medicine 7:212–35.Google Scholar
DeVita, V. T. and Serpik, A.. 1967. “Combination Chemotherapy in the Treatment of Advanced Hodgkin‘s Disease.“ proceedings of the American Association for Cancer Research 8:13–18.Google Scholar
Dornheim, J. 1991. “Images and Interpretation of Severe Illness: Ethological Aspects of Dealing with Cancer.“ Anthropologies of Medicine. 7:157–73.Google Scholar
Edincott, K. M. 1957. “The Chernotherapy Program” Journal of the National Cancer Institute 19:275–93.Google Scholar
Farber, S. L. K. Diamond, R. D. Mercer, et al. 1948. “Temporary Remission in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4–Aminoptenyl–Glutamic Acid (Aminopterin).“ New England Journal of Medicine 238:787–93.Google Scholar
Feenberg, A. 1991. Critical Theory of Technology. New York:Oxford University Press.Google Scholar
Frei, E., and Freireich, E. J. 1965. “Progress and Perspectives in the Chemotherapy of Acute Leukemia.“ Advances in Chemotherapy 2:269–98.CrossRefGoogle ScholarPubMed
Freidson, E. 1961. Patient‘s View of Medical Proctice. New York:Russell Sage Foundation.Google Scholar
Freireich, E. J. 1979. “Should the Patient Know?“ Journal of the American Medical Association 241:928.Google ScholarPubMed
Geertz, C. 1973. “Thick Description: Toward an Interpretative Theory of Culture.” In his The Interpretation of Cultures, 3–30. New York: Basic Books.Google Scholar
Gifford, F. 1986. “The Conflict between Randomized Clinical Trials and the Therapeutic Obligation.“ Journal of Medincine and Philosophy 11:347–66.CrossRefGoogle ScholarPubMed
Gordon, D. R. 1991. “Culture, Cancer and Communication in Italy“ Anthropologies of Medicine 7:137–56.CrossRefGoogle Scholar
Hayes, D. F. 1991. “What Would You Do if This Were Your … Wife, Sister, Mother, Self?“ Journal of Clinical Oncology 9:1–3.CrossRefGoogle Scholar
Hertz, R. Lewis, J. Lipsett, M. B.. 1963. “Five Years‘ Experience with the Chemotherapy of Metastatic Trophoblastic Diseases in Women.“ American Journal of Obstetrics and Gynecology 86:808–14.CrossRefGoogle Scholar
Illich, I. 1976. The Medical Nemesis: The Expropriation of Health. New York:Pantheon.Google Scholar
Jasmin, C. 1983. Parce que je crois au lendemain. 70–79. Paris:Editions Robert Lafont.Google Scholar
Kenedy, B. J. et al. “Training Program in Medical Oncology.“ Annals of Internal Medicine 78:127–30.CrossRefGoogle Scholar
Kother, R. 1991. “Systems of Production: Drosophila, Neurospora and Biochemical Genetics.“ Historical Studies in the Biological and the Physical Sciences 21:87–127.Google Scholar
Krant, M. J., Cohen, J. L., and Rosenbaum, C. 1977. “Moral Dilemmas in Clinical Cancer Experimentation.“ Medical and Pediatric Oncology 3:141–47.CrossRefGoogle ScholarPubMed
Lellouch, J. and Schwartz, D.1971 “L‘essai theérapeutique: éthique individuelle ou ethique collective?“ Revue de l‘Institut International de Statistique 39:127–36.Google Scholar
Li, M. C. 1971. “Trophoblastic Disease: Natural History, Diagnosis and Treatment.“ Annals of Internal Medicine 74:102–12.CrossRefGoogle ScholarPubMed
Li, M. C., Hertz, R, and Spencer, D. B.. 1956. “Effect of Methotrexate upon Choriocarcinoma and Chorioadenoma.“ Proceedings of the Society for Experimental Biology and Medicine 93:361–66.CrossRefGoogle Scholar
MacGregor, A. B. 1966. “The Search for a Chemical Cure for Cancer.“ Medical History 10:374–85.CrossRefGoogle ScholarPubMed
Mackillop, W. J., Ward, G. K., and Sulliven, B. 1986. “The Uses of Expert Surrogates to Evaluate Clinical Trials in Non–Small Cell Lung Cancer.“ British Journal of Cancer 54:661–67.CrossRefGoogle Scholar
Mackillop, W. J., Palmer, M. J., O‘Sullivan, B et al. 1989. “Clinical Trials in Cancer: The Role of Surrogate Patinets in Defining What Constitutes an Ethically Acceptable Clinical Experiment.“ British Journal of Cancer 59:388–95.CrossRefGoogle Scholar
Marks, H. K. 1987. Ideas as Reforms: Therapeutic Experiments and Medical Practice. PhD. diss, MIT.Google Scholar
Merton, R. K. 1973. The Sociology of Science: Theoretical and Empirical Investigations. Chicago:University of Chicago Press.Google Scholar
Novack, D. H., Plumer, R, Smith, R. L. et al. 1979. “Changes in Physicians‘ Attitudes toward Telling the Cancer Patient.“ Journal of the American Medical Association 241:897–900.CrossRefGoogle ScholarPubMed
Oldham, R. K. 1985. “The Cure for Cancer.“ Journal of Biological Response Midifiers 4:111–16.Google ScholarPubMed
Palmer, M. J., O‘Sullivan, B, Steele, R, and Mackillop, W. J.. 1990. “Controversies in the Management of Non–Small Cell Lung Cancer: The Results of Expert Surrogate Study.“ Radiotherapy and Oncology 19:17–27.CrossRefGoogle ScholarPubMed
Patterson, J. 1987. The Dread Disease: Cancer and Modern American Culture. Cambridge, Mass.:Harvard University Press.CrossRefGoogle Scholar
Peckham, M. J. 1981. “Clinical Oncology: The Future of Radiotherapy and Medical Oncology.“ The Lancet i:886–87.CrossRefGoogle Scholar
Pinch, T., and Bijker, W. 1987. “The Social COnstruction of Facts and Artifacts.“ In The Social Construction of Technological Systems, Pinch, T, Hughes, T. B., and Bijker, W. Cambridge, Mass.:MIT Press.Google Scholar
Porter, F. E. 1987. “Bioethics.“ Journal of Biological Response Modifiers 6:369–74.Google ScholarPubMed
Porter, T. M. 1992. “statistics and the Politics of Objectivity.“ Paper presented at the Ecole Pratique des Hautes Etudes, Paris, April.Google Scholar
Radstone, D. 1988. “The Physician‘s Attitude in Britain.“ In Cost versus Brnefit in Cancer Care, Stoll, B. A., 49–56. Baltimore.:The Johns Hopkins University Press.Google Scholar
Rees, G. J. G. 1985. “Cost Effectiveness in Oncology.“ Lancet ii:1405–1407.CrossRefGoogle Scholar
Rees, G. J. G. 1988. “What Is Best for the Patient? A European View.“ In Cost versus Benefit in Cancer Care, Stoll, B. A., 31–38. Baltimore:The Johns Hopkins University Press.CrossRefGoogle Scholar
Resier, S. J. 1980. “Words as Scalpels: Transmitting Evidence in a Clinical Dialogue.“ Annals of Internal Medicine 92:837–42.CrossRefGoogle Scholar
Robinson, I. 1990. “Clinical Trials and the Collective Ethics: The Case of Hyperbaric Oxygen Therapy and the Treatment of Multiple Sclerosis.“ In Social Science Perspectives on Medical Ethics, Weisz, G, 19–41. Dordrecht:Kluwer.CrossRefGoogle Scholar
Rosenberg, C. 1990. “Looking Forward, Thinking Backward: The Roots of the Hospital Crisis.“ Trnsactions and Studies of the College of Physicians of Philadelphia, ser. 5, 12:124–50.Google Scholar
Rothman, D. J., and Edgar, H. 1992. “Scientific Rigor and medical Realities: Placebo Trials in Cancer and AIDS Research.“ In AIDS — The Making of a Chronic Disease, Fee, E and Fox, D. M., 194–206. Berkeley:California University Press.Google Scholar
Roy, D. J. 1986. “Editorial: Controlled Clinical Trials: An Ethical Imperative.“ Journal of Chronic Diseases 39:159–62.CrossRefGoogle ScholarPubMed
Schaffner, K. F. 1986. “Ethical Problems in Clinical Trials.“ journal of Medicine and Philosophy 11:347–66.CrossRefGoogle ScholarPubMed
Stoll, B. A. 1983. “Quality of Life as an Objective in Cancer Treatment.“ In Cancer Treatment: End Point Evaluation, Stoll, B. A., 113–38. London:Wiley.Google Scholar
Stoll, B. A. 1988. “Saying No Is Difficult in Cancer.“ In Cost versus Benefit in Cancer Care, Stoll, B. A., 97–111. Baltimore:The Johns Hopkins University Press.Google Scholar
Tobias, J. S.,Harper, P. G., and Tattersall, M. H. N.. 1981. “Who Should Treat Cancer?“ The Lancet i:885–86.Google Scholar
Vanderpool, H. Y. 1985. “The Ethics of Clinical Experimentatin with Anticancer Drugs. In Cancer Treatment in Humanistic Perspective, Gross, S. C. and Grab, S, 16–46. New York:Springer.Google Scholar
Watson, J. V. 1981. “What Does ‘Response‘ in Cancer Therapy Really Mean?“ British Medical Journal 283:34–37.CrossRefGoogle ScholarPubMed
Weisz, G., ed. 1990. Social Science Perspectives on Medical Ethics. Dordrech:Kluwer.CrossRefGoogle Scholar
“Who Should Treat Cancer?“ 1981. The Lancet ii:674–75.Google Scholar
Wright, J. C. 1984. “Cancer Chemotherapy: Past, Present and Future.“ Journal of the National medical Association 78:773–83.Google Scholar
Zubord, C. G. 1979. “Historic Milestones in Curative Chemotherapy.“ Seminars in Oncology 6(4):490–505.Google Scholar
Zubord, C. G. 1984. “Origins and Development of Chemotherapy Research at the National Cancer Institute.“ Cancer Treatment Reports 68:9–19.Google Scholar
Zubord, C. G.,Schepartz, S. A., and Carter, S. K.. 1977. “Historical Background of the National Cancer Institute‘s Drug Development Thrust.“ National Cancer Institute Monograph 45:7–11.Google Scholar